Compare · ALMS vs JNJ
ALMS vs JNJ
Side-by-side comparison of Alumis Inc. (ALMS) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMS and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $618.61B, about 171.4x ALMS ($3.61B).
- Over the past year, ALMS is up 687.8% and JNJ is up 63.8% - ALMS leads by 623.9 points.
- ALMS has been more active in the news (8 items in the past 4 weeks vs 5 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 13 for ALMS).
- Company
- Alumis Inc.
- Johnson & Johnson
- Price
- $28.32-6.60%
- $256.93-0.82%
- Market cap
- $3.61B
- $618.61B
- 1M return
- +41.67%
- +8.41%
- 1Y return
- +687.76%
- +63.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 8
- 5
- Recent ratings
- 13
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ALMS
- Chief Legal Officer Pangali Sanam sold $140,000 worth of shares (5,000 units at $28.00) and exercised 5,000 shares at a strike of $5.06 (SEC Form 4)
- Director Tetrault Lynn A. was granted 3,553 shares (SEC Form 4)
- Director Yao Zhengbin was granted 3,553 shares, increasing direct ownership by 15% to 27,082 units (SEC Form 4)
- Director Srivastava Sapna was granted 3,553 shares (SEC Form 4)
- Director Machado Patrick was granted 3,553 shares (SEC Form 4)
- Director Akkaraju Srinivas was granted 3,553 shares (SEC Form 4)
- Alumis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Alumis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Chief Medical Officer Drappa Jorn exercised 26,852 shares at a strike of $6.65, increasing direct ownership by 83% to 59,339 units (SEC Form 4)
- SEC Form DEFA14A filed by Alumis Inc.
Latest JNJ
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
- EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients